REG - Polarean Imaging PLC - Grant of Options & Director Compensation Reduction

Polarean ImagingAnnouncement

09/07/2021 07:00

RNS Number : 6861E
  
Polarean Imaging PLC
  
09 July 2021
  
 

Polarean Imaging Plc 
("Polarean" or the "Company")
 
Grant of Options and Director Compensation Reduction
 
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that upon the recommendation of the Company's Remuneration Committee it has granted options over an aggregate 5,250,000 shares of £0.00037 each in the capital of the Company to certain Directors and employees of the Company pursuant to the terms of the Company's Stock Option Plan (the "Share Options").  In addition, the Company announces that the Chairman and Non-Executive Directors have agreed to reduce their annual cash compensation.  
 
4,450,000 Share Options have been granted to the ten PDMR's listed in the table below and 800,000 Share Options have been granted to eight non-PDMR employees. The Share Options will be exercisable at a price of 93p and will vest 25% on 7 July 2022 with the remaining Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 31 August 2022.
 
 



Name


Share Options Granted


Total no. of options over ordinary shares now held




Richard Hullihen


1,000,000


3,135,440




Jonathan Allis


   500,000


1,034,400




Cyrille Petit


   500,000


   500,000




Charles Osborne


   500,000


1,700,000




Kenneth West


   350,000


2,263,218




Bastiaan Driehuys


   350,000


1,686,000




Juergen Laucht


   350,000


   884,400




Kiarash Emami


   300,000


3,185,548




Neil Wadehra


   300,000


1,568,988




Alexander Dusek


   300,000


1,500,000



 
Notifications have been made in accordance with the requirements of the EU Market Abuse Regulation in respect of the PDMRs and further details can be found by following this link: https://www.polarean-ir.com/content/investors/shareholder-information
 
Dr. Jonthan Allis has agreed to reduce his annual cash compensation from $100,000 to $70,000.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht have agreed reduce their base annual cash compensation from $45,000 to $31,500.  Dr. Bastiaan Driehuys, Mr. Kenneth West, Mr. Cyrille Petit and Mr. Juergen Laucht will continue to receive an additional $5,000 per year for each Board Committee on which they serve.
 
Following the grant of Share Options referred above, there are 26,438,451 outstanding options and warrants over Polarean's Ordinary Shares, representing 12.6% of the Company's total voting rights.
 
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
 
Enquiries:



Polarean Imaging plc


www.polarean.com / www.polarean-ir.com




Richard Hullihen, Chief Executive Officer


Via Walbrook PR




Jonathan Allis, Chairman








 








Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)


+44 (0)20 7710 7600




Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking)








Nick Adams / Fred Walsh (Corporate Broking)


















Walbrook PR


Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com




Paul McManus / Anna Dunphy


Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001










 
 
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space. 
 
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream. 
 
In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.
 
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCRPMPTMTTMBMB